PLD ACQUISITIONS
GenericsPLD ACQUISITIONS is a generic drug manufacturer focused on Immunology, Neurology.
PLD ACQUISITIONS's Key Drugs
PLD ACQUISITIONS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
PLD ACQUISITIONS's Recent FDA Approvals
New NDA/BLA approvals for PLD ACQUISITIONS over the last two years — novel drugs only, excluding generics and label supplements.
PLD ACQUISITIONS's Therapeutic Areas
PLD ACQUISITIONS's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PLD ACQUISITIONS's Top Competitors
PLD ACQUISITIONS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PLD ACQUISITIONS Pipeline Snapshot
Active clinical trials for PLD ACQUISITIONS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1993-10-31
- Latest
- 2024-04-11
- Applications
- 9